Methicillin-resistant Staphylococcus aureus (MRSA) Drugs Market - Insights
Methicillin-resistant Staphylococcus aureus (MRSA) can be classified into two types, based on the mode of infection; hospital-associated MRSA infection (HA-MRSA) and community-associated MRSA infections (CA-MRSA). Various antibacterial agents such as Vancomycin, Daptomycin, Ceftaroline fosamil, Tetracycline, Clindamycine, and Tedizolid phosphate are available in the market for treatment of infections associated with MRSA. According to the Centers for Disease Control and Prevention (CDC) review 2015, around 33% people globally had Staphylococcus aureus (S. aureus) bacteria in their nose, usually without any illness.
Market players are focused on developing and launching new drugs containing antibacterial agents for treating infections associated with MRSA. For instance, in 2018, Destiny Pharma Inc, received investigational new drug application from the U.S. FDA for Exeporfinium Chloride (XF-73), a dicationic porphyrin molecule based nasal gel, to combat post-surgical infections by methicillin-resistant staphylococcus aureus (MRSA). The study is estimated to be completed by December 2019.
The global methicillin-resistant staphylococcus aureus (MRSA) drugs market is estimated to be valued at US$ 922.2 million in 2018, and is expected to register a CAGR of 4.1% during the forecast period (2018–2026).
Figure 1. Global Methicillin-resistant Staphylococcus aureus (MRSA) drugs Market Share (%), By Drug Class, (2018 & 2026)
Source: Coherent Market Insights Analysis (2019)
Increasing Regulatory Approvals for Drugs Is Expected to Drive Global Methicillin-resistant Staphylococcus aureus (MRSA) drugs Market Growth
Approvals and launches of affordable generic medication is expected to drive the global methicillin-resistant Staphylococcus aureus (MRSA) drugs market growth over the forecast period. For instance, in 2015, Glenmark Pharmaceuticals received the approval from the U.S. Food and Drug Administration (FDA) for the generic version of the anti-bacterial drug, Zyvox. Moreover, in 2015, Allergan Plc. received the U.S. FDA approval for supplemental new drug application (sNDA) to update the label of Teflaro (ceftaroline fosamil) for treating adult patients with acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP).
Furthermore, strategic agreements and collaborations by market players regarding distribution of MRSA drugs are expected to drive the market growth. For instance, in 2016, Basilea Pharmaceutica Ltd. entered into a supply, distribution, and license agreement with Grupo Biotoscana S.L., for Basilea's antifungal CRESEMBA (isavuconazole) and antibiotic Zevtera (ceftobiprole) in 19 countries of Latin America along with Brazil, Mexico, Argentina, and Colombia.
However, declining patient pool having infections caused by MRSA pathogen is expected to restrain growth of the global methicillin-resistant staphylococcus aureus (MRSA) drugs market. According to the Centers for Disease Control and Prevention, hospital associated MRSA infections declined by 54% between 2005 and 2011 owing to increasing awareness about personal and public hygiene among the populace. This, in turn, is expected to reduce demand for the drugs.
Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market - Regional Analysis
Regional segmentation of the global methicillin-resistant staphylococcus aureus (MRSA) drugs market includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Among region, North America is expected to hold a dominant position in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market, and is expected to witness significant growth over the forecast period, owing to increasing health awareness, favorable reimbursement scenario, rising healthcare expenditure, and increasing number of approvals and launches of MRSA drugs. For instance, in 2016, Allergan Plc. received the U.S. Food and Drug Administration (FDA) approval for its supplemental new drug application (sNDA) to update the label for Dalvance (dalbavancin) for injection.
Moreover, Asia Pacific is expected to witness significant growth over the forecast period, owing to a larger patient pool, and expansion strategies adopted by market players to increase their market presence. For instance, in 2017, Basilea Pharmaceutica Ltd. entered into a licensed agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. for expansion of Basilea's antibiotic Zevtera, a broad spectrum anti-bacterial, which can address MRSA in China, Hong Kong, and Macao.
Furthermore, Europe is projected to witness significant market growth owing to launches and approvals of new drugs. For instance, in 2017, Cardiome Pharma Corp. launched Xydalba in Sweden, Finland, and the Republic of Ireland. Xydalba is approved by the European Medicines Agency (EMA) for treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults.
Figure 2: Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Share (%), By Region, (2018 & 2026)
Source: Coherent Market Insights Analysis (2019)
Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market - Competitive Landscape
Key players operating in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market include Merck & Co, Inc., Pfizer, Inc., Allergan Plc., Teva Pharmaceutical Industries ltd, Melinta Therapeutics, Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics Plc., Paratek Pharmaceuticals, Inc., Debiopharm International S.A., and Innovation Pharmaceuticals Inc.
Methicillin-resistant staphylococcus aureus (MRSA) is a type of gram positive bacteria, which is resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such antibiotics. Staphylococcus aureus leads to skin infections such as boils, pimples, impetigo, abscesses or certain life threatening conditions such as septicemia (blood poisoning), pneumonia (lung infection), osteomyelitis (bone infection), endocarditis (heart valve infection), urinary tract infection, and septic bursitis (formation of small fluid-filled sacs under the skin).
Growth of the methicillin-resistant staphylococcus aureus (MRSA) drug market is driven by increasing product development. For instance, in 2014, Cubist Pharmaceuticals Inc. received the U.S. FDA approval for its new antibiotic drug, Sivextro, available as an injection and as an oral formulation, to treat skin infection caused by gram positive bacteria MRSA. In March 2017, Durata Therapeutics Inc. initiated phase 3 clinical trials on Dalbavancin to determine the safety and efficacy of Dalbavancin for treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive organism’s methicillin-resistant strains of staphylococcus aureus in children. The study is expected to be completed in October 2019.
Initiatives by various government and private organizations for development of novel MRSA drugs is also expected to be a major factor driving the market growth. For instance, in 2017, Cystic Fibrosis Foundation Therapeutics (CFFT), a non-profit drug discovery and development arm of Cystic Fibrosis Foundation, awarded US$ 5 million to Savara Inc., a clinical-stage specialty pharmaceutical company, for developing AeroVanc, a vancomycin hydrochloride inhalation powder, intended to treat MRSA lung infection in individuals with cystic fibrosis.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 29 market data tables and 31 figures on "Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market” - Global forecast to 2026”.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.